Cell death: targeting ferroptosis in cancer
Abstract
In two recent studies published in Nature , Wu et al. and Palma et al. elegantly demonstrated that the endogenous ferroptosis suppressor AIF family member 2 (AIFM2, best known as FSP1) is a pharmacologically actionable vulnerability in lung carcinoma and metastatic melanoma. 1 , 2 These findings formally validate the notion that activating ferroptosis might constitute a viable strategy to control developing tumors (which often exhibit defects in apoptotic signaling), 3 potentially paving the way to the development of clinically viable ferroptosis inducers for cancer therapy.
Fields of Study & Subjects
Ferroptosis and cancer prognosis
Phagocytosis and Immune Regulation
Clusterin in disease pathology
Publication details
- Journal / source
- Signal Transduction and Targeted Therapy
- Publisher
- Springer Science and Business Media LLC
- Volume
- 11
- Issue
- 1
- Pages
- 5–5
- Publication date
- 2 January 2026
- Language
- EN